Esperion Therapeutics (ESPR) Stock Rating Lowered by BidaskClub
Esperion Therapeutics (NASDAQ:ESPR) was downgraded by equities research analysts at BidaskClub from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday.
Other research analysts also recently issued research reports about the company. ValuEngine downgraded Esperion Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, June 21st. Zacks Investment Research raised Esperion Therapeutics from a “hold” rating to a “buy” rating and set a $48.00 price target for the company in a research note on Tuesday, July 31st. Chardan Capital raised Esperion Therapeutics to a “hold” rating and set a $32.50 price target for the company in a research note on Friday, July 20th. Stifel Nicolaus began coverage on Esperion Therapeutics in a research note on Friday, September 14th. They issued a “buy” rating and a $89.00 price target for the company. Finally, Cowen reaffirmed a “buy” rating and issued a $95.00 price target on shares of Esperion Therapeutics in a research note on Monday, August 6th. Three investment analysts have rated the stock with a sell rating, three have given a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. Esperion Therapeutics has a consensus rating of “Hold” and a consensus target price of $80.58.
ESPR stock opened at $43.16 on Friday. Esperion Therapeutics has a 52 week low of $33.06 and a 52 week high of $82.68.
In other Esperion Therapeutics news, Director Roger S. Newton sold 17,700 shares of Esperion Therapeutics stock in a transaction dated Monday, August 27th. The stock was sold at an average price of $51.05, for a total value of $903,585.00. Following the transaction, the director now owns 615,726 shares in the company, valued at $31,432,812.30. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Roger S. Newton sold 7,300 shares of Esperion Therapeutics stock in a transaction dated Friday, August 17th. The shares were sold at an average price of $50.06, for a total value of $365,438.00. Following the completion of the transaction, the director now owns 616,426 shares in the company, valued at approximately $30,858,285.56. The disclosure for this sale can be found here. In the last quarter, insiders acquired 150,000 shares of company stock worth $6,369,500. Company insiders own 32.50% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the business. Quantbot Technologies LP grew its position in Esperion Therapeutics by 348.6% in the first quarter. Quantbot Technologies LP now owns 1,588 shares of the biopharmaceutical company’s stock valued at $114,000 after acquiring an additional 1,234 shares during the last quarter. Bayesian Capital Management LP bought a new position in Esperion Therapeutics in the first quarter valued at about $231,000. Xact Kapitalforvaltning AB bought a new stake in shares of Esperion Therapeutics during the first quarter worth about $250,000. Keybank National Association OH grew its holdings in shares of Esperion Therapeutics by 97.7% during the second quarter. Keybank National Association OH now owns 7,663 shares of the biopharmaceutical company’s stock worth $300,000 after purchasing an additional 3,787 shares during the last quarter. Finally, Metropolitan Life Insurance Co. NY grew its holdings in shares of Esperion Therapeutics by 40.6% during the second quarter. Metropolitan Life Insurance Co. NY now owns 7,698 shares of the biopharmaceutical company’s stock worth $302,000 after purchasing an additional 2,224 shares during the last quarter.
Esperion Therapeutics Company Profile
Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.
Featured Story: Asset Allocation Models, Which is Right For You?
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.